A new technology, mvGPT, is capable of precisely editing genes, activating gene expression, and repressing genes all at the ...

Prime Medicine has been given the go-ahead by the FDA for the first human trial of its prime editing technology, which promises to deliver one-shot therapies for a range of severe genetic diseases.

Influential inventions often combine existing tools in new ways. The iPhone, for instance, amalgamated the telephone, web ...

The company’s Prime Editing platform provides a unique method for editing DNA sequences that surpasses the capabilities of first-generation gene editing technologies. This versatility allows for ...

to initiate trials of the first-ever prime editing drug. The FDA cleared Prime Medicine’s investigational new drug (IND) application for PM359 for the treatment of chronic granulomatous disease ...

PRME), a clinical-stage biotechnology company specializing in Prime Editing-based therapies, stands at the forefront of gene editing technology. With a current market capitalization of $382.79 ...

Gene-editing biotech Prime Medicine has priced a follow-on public offering, hoping to raise $140 million to advance its pipeline of one-shot therapies for severe genetic disorders. The Cambridge ...

Prime Medicine, Inc. (NASDAQ:PRME), a clinical-stage biotechnology company specializing in Prime Editing-based therapies, stands at the forefront of gene editing technology. With a current market ...